Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition

Hypertension

Volumn 44, Issue 6, 2004, Pages 974-981

  Ortmann, Jana ^a   Amann, Kerstin ^b   Brandes, Ralf P ^c   Kretzler, Matthias ^d   Münter, Klaus ^e   Parekh, Niranjan ^f   Traupe, Tobias ^a   Lange, Melanie ^a   Lattmann, Thomas ^a   Barton, Matthias ^a,g  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e BAYER AG   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

Author keywords

Arterial presure; DNA; Expression; Kidney; Kidney failure; Nephrosclerosis; Renal artery; Renal disease

Indexed keywords

DARUSENTAN; ENDOTHELIN; ENDOTHELIN A RECEPTOR; GELATINASE B; PROTEIN P21; PUROMYCIN AMINONUCLEOSIDE;

AGING; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CYTOSKELETON; DNA SYNTHESIS; GLOMERULOSCLEROSIS; GLOMERULUS; GLOMERULUS FILTRATION RATE; HISTOLOGY; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RNA INTERFERENCE;

AGING; ANIMALS; APOPTOSIS; BLOOD PRESSURE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; DNA; ENDOTHELIN-1; GENE EXPRESSION; GENE SILENCING; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; KIDNEY; KIDNEY GLOMERULUS; MALE; MATRIX METALLOPROTEINASE 9; PHENYLPROPIONATES; PROTEINURIA; PYRIMIDINES; RATS; RATS, WISTAR; RECEPTOR, ENDOTHELIN A; SIGNAL TRANSDUCTION;

EID: 9644282849     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000149249.09147.b4     Document Type: Article

References (40)

1. Lewis WH, Alving AS. Changes with age in the renal function in adult men. Am J Physiol. 1938;123:500-515.
2. Anderson S, Brenner BM. The aging kidney: structure, function, mechanisms, and therapeutic implications. J Am Geriatr Soc. 1987;35:590-593.
3. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
4. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest. 2001;108:1583-1587.
5. Kriz W, Gretz N, Lemley KV. Progression of glomerular disease: is the podocyte the culprit? Kidney Int. 1998;54:687-697.
6. White KE, Bilous RW; Diabiopsies Study Group. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant. 2004;19:1437-1440.
7. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003;83:253-307.
8. WAf1/cip1: more than a break to the cell cycle? Biochim Biophys Acta. 2000;1471:M43-M56.
9. Melk A, Halloran PF. Cell senescence and its implications for nephrology. J Am Soc Nephrol. 2001;12:385-393.
10. Megyesi J, Price PM, Tamayo E, Safirstein RL. The lack of a functional p21(WAF1/CIp1) gene ameliorates progression to chronic renal failure. Proc Natl Acad SCI USA. 1999;96:10830-10835.
11. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
12. Benigni A, Perico N, Remuzzi G. Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Curr Opin Nephrol Hypertens. 2001;10:1-6.
13. Barton M, Lattmann T, d'Uscio LV, Luscher TF, Shaw S. Inverse regulation of endothelin-1 and nitric oxide metabolites in tissue with aging: implications for the age-dependent increase of cardiorenal disease. J Cardiovasc Pharmacol. 2000;36:S153-S156.
14. Goettsch W, Lattmann T, Amann K, Szibor M, Morawietz H, Munter K, Muller SP, Shaw S, Barton M. Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo: implications for atherosclerosis. Biochem Biophys Res Commun. 2001;280:908-913.
15. Rebibou JM, He CJ, Delarue F, Peraldi MN, Adida C, Rondeau E, Sraer JD. Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant, 1992:7:288-292.
16. Riechers H, Albrecht HP, Amberg W, Baumann E, Bernard H, Bohm HJ, Klinge D, Kling A, Muller S, Raschack M, Unger L, Walker N, Wernet W. Discovery and optimization of a novel class of orally active non-peptidic endothelin-A receptor antagonists. J Med Chem. 1996;39:2123-2128.
17. Amann K, Munter K, Wessels S, Wagner J, Balajew V, Hergenroder S, Mall G, Ritz E. Endothelin A receptor blockade prevents capillary/ myocyte mismatch in the heart of uremic animals. J Am Soc Nephrol. 2000;11:1702-1711.
18. Parekh N, Dobrowolski L, Zou AP, Steinhausen M. Nitric oxide modulates angiotensin II- and norepinephrine-dependent vasoconstriction in rat kidney. Am J Physiol. 1996;270:R630-R635.
19. Hall JE, Guyton AC, Farr BM. A single-injection method for measuring glomerular filtration rate. Am J Physiol. 1977;232:F72-F76.
20. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, Ehmke H, Rump LC, Ritz E. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int. 2001;60:1309-1323.
21. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, Schleuning WD, Theuring F. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest. 1997;99:1380-1389.
22. Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, Kummer W, Bohle R. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med. 1998;4:1329-1333.
23. Smoyer WE, Ransom RF. Hsp27 regulates podocyte cytoskeletal changes in an in vitro model of podocyte process retraction. FASEB J. 2002;16:315-326.
24. Reiser J, Pixley FJ, Hug A, Kriz W, Smoyer WE, Stanley ER, Mundel P. Regulation of mouse podocyte process dynamics by protein tyrosine phosphatases. Kidney Int. 2000;57:2035-2042.
25. Kretzler M, Teixeira VP, Berger T, Blattner SM, Unschuld PG, Cohen CD, Schlondorff D. Altering glomerular epithelial function in vitro using transient and stable transfection. J Nephrol. 2001;14:211-219.
26. Tuschl T. RNA interference and small interfering RNAs. Chembiochem. 2001;2:239-245.
27. Kretzler M, Teixeira VP, Unschuld PG, Cohen CD, Wanke R, Edenhofer I, Mundel P, Schlondorff D, Holthofer H. Integrin-linked kinase as a candidate downstream effector in proteinuria. FASEB J. 2001;15:1843-1845.
28. A-receptor antagonist, reduces proteinuria in patients with diabetes mellitus. In: Regulation of Vascular Tone in Humans by Endothelium-Derived Mediators [thesis]. Utrecht, The Netherlands: Elinkwijk BV; 2000:89-102.
29. Remuzzi A, Gagliardini E, Donadoni C, Fassi A, Sangalli F, Lepre MS, Remuzzi G, Benigni A. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int. 2002;62:885-894.
30. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptors antagonism and matrix metalloproteinases. J Am Soc Nephrol. 2003;14:1132-1144.
31. A receptors for endothelin regulation. Biochem Biophys Res Commun. 1997;238:861-865.
32. Zoja C, Remuzzi A, Corna D, Perico N, Bertani T, Remuzzi G. Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. Am J Med. 1992;92:60S-63S.
33. Remuzzi A, Imberti O, Puntorieri S, Malanchini B, Macconi D, Magrini L, Bertani T, Remuzzi G. Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats. Am J Physiol 1994;267:F1034-F1044.
34. Vielhauer V, Berning E, Eis V, Kretzler M, Strutz F, Horuk R, Grone HJ, Schlondorff D, Anders HJ. CC-chemokine receptor 1 blockade reduces interstitial fibrosis in mice with focal segmental glomerular sclerosis and nephrotic syndrome. Kidney Int. In press.
35. Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, D'Agati V, Alpers CE. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int. 2000;58:674-683.
36. Ding G, Franki N, Kapasi AA, Reddy K, Gibbons N, Singhal PC. Tubular cell senescence and expression of TGF-betal and p21 (WAF1/CIP1) in tubulo-interstitial fibrosis of aging rats. Exp Mol Pathol. 2001;70:43-53.
37. Di Cunto F, Topley G, Calautti E, Hsiao J, Ong L, Seth PK, Dotto GP. Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science. 1998;280:1069-1072.
38. Martin J, Davies M, Thomas G, Lovett DH. Human mesangial cells secrete a GBM-degrading neutral proteinase and a specific inhibitor. Kidney Int. 1989;36:790-801.
39. Davies M, Martin J, Thomas GJ, Lovett DH. Proteinases and glomerular matrix turnover, Kidney Int. 1992;41:671-678.
40. Morigi M, Zoja C, Angioletti S, Zanchi C, Longaretti L, Donadelli R, Mundel P, Benigni A, Remuzzi G. Podocytes respond to protein overload by cytoskeleton rearrangement and upregulation of AP-1 dependent endothelin-1 (ET-I) gene expression. J Am Soc Nephrol. 2001;12:686A (abstract).